Typically, patients who may benefit from ivabradine are those with HFrEF who have NYHA (New York Heart Association) class II or class III symptoms (see table) and heart rate > 70 beats / minute who are at target beta-blocker dose or cannot tolerate a further increase in beta-blocker dose (8).